– Multi-year collaboration to identify up in order to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine
– Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, plus sales-based milestones, and tiered royalties

NORTH CHICAGO, Ill. and EXTON, Pa. , Jan. 6, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell system to discover and develop first-in-class antibody therapeutics, today announced the worldwide collaboration and option agreement directed to the discovery of up in order to 10 novel antibody-target sets arising from three specified tumor types using Immunome’s Discovery Engine.

“Partnering with Immunome represents AbbVie’s commitment to developing plus commercializing novel treatment approaches for solid tumors, ” said Steve Davidsen , Ph. D., vice president, oncology discovery research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates. We look forward in order to utilizing their Discovery Motor to enhance our existing oncology pipeline. inch

“This cooperation with AbbVie, a true leader in the advancement and commercialization of oncology therapeutics, demonstrates the strength of Immunome’s Discovery Engine, ” said Purnanand Sarma , Ph. D., chief executive and CEO of Immunome. “AbbVie shares our vision of harnessing the power associated with the human being immune response to yield book and first-in-class therapeutics that represent a shift within the cancer finding paradigm. We are delighted to be working with AbbVie plus look forward to leveraging their vast development and commercialization expertise in bringing new therapies to patients suffering from life-threatening cancers. This collaboration fits nicely within Immunome’s strategy to maximize the new drug discovery possible of our Finding Engine through partnerships across multiple therapeutic segments, in addition to advancing our own proprietary pipeline. ”

Under the particular terms of the agreement, Immunome will grant AbbVie the option in order to purchase worldwide rights for up to 10 book target-antibody pairs arising through the selected tumors. Immunome will receive an upfront payment of $30M plus will be eligible to get additional platform access obligations in the aggregate amount of up to $70M based on AbbVie’s election for Immunome to continue research using its Discovery Engine. Immunome is also eligible to obtain development and first commercial sale breakthrough of up to $120M per target with respect to certain products derived from target-antibody sets that AbbVie elects to purchase, with possibility of further sales-based milestones as well as tiered royalties on global sales.  

About AbbVie

AbbVie’s mission is to discover plus deliver innovative medicines that will solve serious health issues today and address the medical challenges associated with tomorrow. We strive to have a remarkable impact on people’s lives across several key restorative areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, within addition in order to products and services throughout its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter , Facebook , Instagram , YouTube and LinkedIn

About Immunome

Immunome is the biopharmaceutical company which utilizes its proprietary individual memory W cell system to discover plus develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is upon discovering and developing therapeutics in oncology internally and in collaboration with our partners. To find out more, please visit  www.immunome.com   or follow us on Twitter   plus LinkedIn .

Regarding Immunome’s Breakthrough Engine

Immunome’s proprietary Discovery Motor identifies story therapeutic antibodies and their own targets by leveraging memory B cells, highly educated components of the immune system, isolated from individuals. Memory M cells are usually key elements in the human immune system reaction to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome’s Breakthrough discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory N cell repertoires to recognize antibodies directed at new targets. The functional data we generate differentiates the approach from those that use deep sequencing of T cells in order to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark associated with therapeutic utility.

Forward-Looking Statements

This press release includes particular disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” from liability established simply by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome’s beliefs and expectations regarding, among other things: Immunome’s and its collaborators’ ability to achieve anticipated discovery, growth and commercial milestones the timing plus results of preclinical studies and clinical trials; medical plans; general regulatory actions; translation associated with preclinical information into scientific safety and efficacy; plus therapeutic potential and benefits of, and possible need and demand for, product candidates which are not historical fact. Forward-looking statements may be identified by the words “anticipate, ” “believe, ” “estimate, ” “expect, ” “intend, ” “plan, ” “project, ” “suggest, ” “can, ” “may, ” “will, ” “could, ” “should, ” “seek, ” “potential” and similar expressions. Forward-looking statements are based on Immunome’s current expectations and are subject in order to inherent uncertainties, risks plus assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the fact that research and development data are subject to differing interpretations and assessments; Immunome’s ability to execute on the strategy, including collaborations along with third parties, including with respect to its R& D efforts, IND submissions and other regulatory filings, timing of these filings and the particular timing plus nature associated with governmental authority feedback concerning the same, initiation and completion of any clinical studies, confirmatory testing plus other expected milestones as and when anticipated; the effectiveness of Immunome’s item candidates, including the possibility that will further preclinical data and any medical trial data may become inconsistent with the information used for advancing the product applicants and that further variants of concern can emerge; Immunome’s capability to fund operations plus raise capital; Immunome’s reliance on vendors; Immunome’s relationships with its collaborators; the competitive landscape; the particular impact associated with the COVID-19 pandemic upon Immunome’s business, operations, strategy, goals and anticipated milestones; and the additional risks and questions set forth more fully under the caption “Risk Factors” in Immunome’s Annual Report on Form 10-K filed with the particular United States Securities and Exchange Commission (SEC) on March 28, 2022 , plus elsewhere within Immunome’s some other filings and reports along with the SEC. Forward-looking statements contained in this announcement are made as of this date, plus Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or even otherwise, except as might be required below applicable law. In this particular pr release, we may discuss our present and possible future product candidates that have not yet completed scientific trials or been approved for marketing by the U. S. Food and Drug Administration or even other governmental authority, which includes expectations regarding their healing potential and benefits thereof. No representation is made because to the particular safety or effectiveness of these current or potential future item candidates for the use for which such product candidates are being studied.


Leave a Reply

Your email address will not be published. Required fields are marked *